Feed DAWN
DA

Day One Biopharmaceuticals, Inc.

DAWN · NASDAQ

$21.53 +0.00% (+$0.00)
Market Cap $2.22B
P/E Ratio -
Div. Yield -
ROE 32.05%

Bulios Fair Price

$13.04

39.4% downside

Current Price

$21.53

Undervalued Fair Value Overvalued

According to Bulios Fair Price, DAWN is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
3/9
Valuation
19 /100
Expensive
P/S 16.64x
P/B 4.93x
P/E N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Gross margin 89.44%
Net margin 113.53%
Op. margin 123.90%
Quality
3 /100
Poor
ROIC 37.82%
ROE 32.05%
ROA 29.54%
Debt
100 /100
Low
Debt/Equity 0.01x
Current ratio 8.68x
Net debt/EBITDA 0.28x
Stability
45 /100
Moderate
Beta -1.75x
EPS volatility 34.05%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about DAWN
Online

About the company

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib.

Sector

Healthcare

Industry

Biotechnology

CEO

Jeremy Bender

Employees

181

Headquarters

Brisbane

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.